Published in J Psychiatr Res on January 01, 1990
Anhedonia and substance dependence: clinical correlates and treatment options. Front Psychiatry (2011) 1.17
Neural reactivity to rewards and losses in offspring of mothers and fathers with histories of depressive and anxiety disorders. J Abnorm Psychol (2014) 1.06
Anhedonia in schizophrenia and major depression: state or trait? Ann Gen Psychiatry (2009) 1.01
Neurogenetics of depression: a focus on reward processing and stress sensitivity. Neurobiol Dis (2012) 1.00
['Pharmacologic interventions in drug addiction': an advisory report from the Health Council of the Netherlands]. Ned Tijdschr Geneeskd (2003) 1.61
Heroin self-administration by means of 'chasing the dragon': pharmacodynamics and bioavailability of inhaled heroin. Eur Neuropsychopharmacol (2001) 1.43
[Frontotemporal dementia in a young woman with apparent schizophrenia]. Ned Tijdschr Geneeskd (1998) 1.42
Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry (1998) 1.36
Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva. Clin Pharmacol Ther (1978) 1.23
Disrupting circadian rhythms in rats induces retrograde amnesia. Physiol Behav (1985) 1.07
Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl (2000) 1.05
The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology (2000) 1.05
Increased gabaergic input to ventral tegmental area dopaminergic neurons associated with decreased cocaine reinforcement in mu-opioid receptor knockout mice. Neuroscience (2005) 1.04
Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. Psychopharmacology (Berl) (1995) 1.03
Brain correlates of memory dysfunction in alcoholic Korsakoff's syndrome. J Neurol Neurosurg Psychiatry (1999) 1.02
Oxytocin but not vasopressin facilitates social recognition following injection into the medial preoptic area of the rat brain. Eur Neuropsychopharmacol (1991) 1.01
Low doses of oxytocin facilitate social recognition in rats. Psychopharmacology (Berl) (1992) 0.98
Serotonergic blunting to meta-chlorophenylpiperazine (m-CPP) highly correlates with sustained childhood abuse in impulsive and autoaggressive female borderline patients. Biol Psychiatry (2000) 0.98
The bovine protein alpha-lactalbumin increases the plasma ratio of tryptophan to the other large neutral amino acids, and in vulnerable subjects raises brain serotonin activity, reduces cortisol concentration, and improves mood under stress. Am J Clin Nutr (2000) 0.97
Regulation of masculine sexual behavior: involvement of brain opioids and dopamine. Brain Res Brain Res Rev (1995) 0.96
The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects. Psychopharmacology (Berl) (1998) 0.96
Neurohypophyseal peptides and social recognition in rats. Prog Brain Res (1998) 0.94
Effects of single and repeated oral administration of fluvoxamine on extracellular serotonin in the median raphe nucleus and dorsal hippocampus of the rat. Neuropharmacology (1995) 0.94
Decrease in basal dopamine levels in the nucleus accumbens shell during daily drug-seeking behaviour in rats. Brain Res (2002) 0.93
Hla, and the response to treatment with gamma-type endorphins in schizophrenia. J Immunogenet (1982) 0.93
Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects. Neuropsychopharmacology (1997) 0.93
The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers. Psychopharmacology (Berl) (1998) 0.92
Intravenous self-administration of drugs in rats. J Pharmacol Exp Ther (1978) 0.92
Prolyl-leucyl-glycinamide (PLG) facilitates morphine dependence. Life Sci (1976) 0.91
Opioids and sexual behavior of male rats: involvement of the medial preoptic area. Behav Neurosci (1995) 0.90
Intracerebroventricular naltrexone treatment attenuates acquisition of intravenous cocaine self-administration in rats. Pharmacol Biochem Behav (1991) 0.90
D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology (1999) 0.90
Short duration of retroactive facilitation of social recognition in rats. Physiol Behav (1991) 0.89
P50 suppression and prepulse inhibition of the startle reflex in humans: a correlational study. Biol Psychiatry (1999) 0.89
Oxytocin in obsessive compulsive disorder. Peptides (1993) 0.89
Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol (1987) 0.88
Short-term isolation increases social interactions of male rats: a parametric analysis. Physiol Behav (1982) 0.88
Recognition cue in the rat's social memory paradigm. J Basic Clin Physiol Pharmacol (1992) 0.88
Psychoeducation of partners of bipolar-manic patients. J Affect Disord (1991) 0.87
The effects of haloperidol on the EEG spectrum. Psychopharmacology (Berl) (1981) 0.87
The interaction between gamma-type endorphins and HLA class I antigens. Hum Immunol (1986) 0.87
Effects of morphine and beta-endorphin on basal and elevated plasma levels of alpha-MSH and vasopressin. Life Sci (1979) 0.87
Vasopressin and memory. Pharmacol Ther (1983) 0.87
Scheduled eating increases dopamine release in the nucleus accumbens of food-deprived rats as assessed with on-line brain dialysis. Neurosci Lett (1988) 0.87
Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients. Psychopharmacology (Berl) (1994) 0.86
Flesinoxan dose-dependently reduces extracellular 5-hydroxytryptamine (5-HT) in rat median raphe and dorsal hippocampus through activation of 5-HT1A receptors. J Neurochem (1996) 0.86
The dopamine metabolite 3-methoxytyramine is not a suitable indicator of dopamine release in the rat brain. J Neurochem (1986) 0.86
Biological dissection of anxiety disorders: the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine. Int Clin Psychopharmacol (1995) 0.86
Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry (1996) 0.86
Behavioral and electrophysiological effects of peptides related to lipotropin (beta-LPH). J Pharmacol Exp Ther (1978) 0.85
Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl) (1994) 0.85
Altered lipid metabolism in apolipoprotein E-deficient mice does not affect cholesterol balance across the liver. Hepatology (1996) 0.85
Opioid blockade attenuates acquisition and expression of cocaine-induced place preference conditioning in rats. Psychopharmacology (Berl) (1995) 0.85
A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. J Clin Psychopharmacol (1996) 0.84
Central target for the behavioural effects of vasopressin neuropeptides. Nature (1984) 0.84
Kinetics of l-5-hydroxytryptophan in healthy subjects. Psychiatry Res (1982) 0.84
Treatment of non-fluctuating progressive dystonia: a neuropharmacological approach. Neuropediatrics (1984) 0.84
Influence of buprenorphine, butorphanol and nalbuphine on the initiation of intravenous cocaine self-administration in drug naive mice. Eur Neuropsychopharmacol (2000) 0.83
Cholecystokinin in anxiety. Eur Neuropsychopharmacol (1996) 0.83
Induction of tolerance to the analgesic action of lipotropin in C-fragment. Nature (1977) 0.83
Behavioral, neuroendocrine, and biochemical effects of 5-hydroxytryptophan administration in panic disorder. Psychiatry Res (1990) 0.83
Lack of evidence for an involvement of nucleus accumbens dopamine D1 receptors in the initiation of heroin self-administration in the rat. Psychopharmacology (Berl) (1994) 0.83
A controlled trial with ORG 2766, an ACTH-(4-9) analog, in 50 relatively able children with autism. Eur Neuropsychopharmacol (1996) 0.83
Social memory in the rat: circadian variation and effect of circadian rhythm disruption. Physiol Behav (2001) 0.83
Social play in juvenile rats after in utero exposure to morphine. Neurotoxicology (1997) 0.83
Naloxone inhibits the reinforcing and motivational aspects of cocaine addiction in mice. Life Sci (1997) 0.83
Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol (1988) 0.83
Serotonin syndrome after challenge with the 5-HT agonist meta-chlorophenylpiperazine. Psychiatry Res (1998) 0.82
Sexual motivation: involvement of endogenous opioids in the ventral tegmental area. Brain Res (1996) 0.82
The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Neuropsychopharmacology (2001) 0.82
Structure activity relationship studies with C-terminal fragments of vasopressin and oxytocin on avoidance behaviors of rats. J Pharmacol Exp Ther (1987) 0.82
Responders and non-responders to drug treatment in social phobia: differences at baseline and prediction of response. J Affect Disord (1996) 0.82
Prenatal exposure to morphine affects juvenile play behavior and adult social behavior in rats. Pharmacol Biochem Behav (1996) 0.82
Endorphins implicated in stereotypies of tethered sows. Experientia (1986) 0.82
Effect of neurohypophyseal hormones on morphine dependence. Psychoneuroendocrinology (1977) 0.82
des-Tyr1-gamma-endorphin and haloperidol increase pineal gland melatonin levels in rats. Peptides (1983) 0.82
Cerebrospinal fluid 5-hydroxyindolacetic acid and aggression: a critical reappraisal of the clinical data. Int Clin Psychopharmacol (1995) 0.82
Dependence creating properties of lipotropin C-fragment (beta-endorphin): evidence for its internal control of behavior. Life Sci (1979) 0.81
Noradrenaline concentrations and electrocardiographic abnormalities after aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry (1995) 0.81
Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. Int Clin Psychopharmacol (1987) 0.81
Analysis of spontaneous alcohol drinking in rhesus monkeys. Physiol Behav (1990) 0.81
Analysis of the influence of vasopressin neuropeptides on social recognition of rats. Eur Neuropsychopharmacol (1991) 0.81
Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology (Berl) (1990) 0.81
A heroin-, but not a cocaine-expecting, self-administration state preferentially alters endogenous brain peptides. Eur J Pharmacol (1999) 0.80
Group therapy in addition to lithium therapy in patients with bipolar disorders. Acta Psychiatr Belg (1988) 0.80
Effects of context on judgements of odor intensities in humans. Chem Senses (1998) 0.80
delta 1-Tetrahydrocannabinol but not cannabidiol reduces contact and aggressive behavior of rats tested in dyadic encounters. Psychopharmacology (Berl) (1984) 0.80
Frontal lobe damage and thalamic volume changes. Neuroreport (2000) 0.80
A double-blind comparative study of remoxipride and haloperidol in acute schizophrenia. Acta Psychiatr Scand Suppl (1990) 0.80
Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology (Berl) (1997) 0.80
Neurohypophyseal principles and memory processes. Biochem Pharmacol (1978) 0.80
Chronic treatment with fluvoxamine by osmotic minipumps fails to induce persistent functional changes in central 5-HT1A and 5-HT1B receptors, as measured by in vivo microdialysis in dorsal hippocampus of conscious rats. Psychopharmacology (Berl) (1995) 0.80
The effect of stress on the dexamethasone suppression test. Psychiatry Res (1985) 0.80
Selective monoamine uptake inhibitors and a serotonin antagonist in the treatment of panic disorder. Psychopharmacol Bull (1989) 0.80
Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder. Psychopharmacology (Berl) (1998) 0.80
Effects of the 5-HT1A receptor agonist flesinoxan in panic disorder. Psychopharmacology (Berl) (1996) 0.80
Naltrexone attenuates self-injurious behavior in mentally retarded subjects. Biol Psychiatry (1990) 0.80